维生素D3辅助治疗对儿童支气管哮喘的肺功能及气道炎症的改善作用研究

Effects of vitamin D3 adjuvant therapy on pulmonary function and airway inflammation in children with bronchial asthma

目的探讨维生素D3辅助治疗对儿童支气管哮喘的肺功能及气道炎症的改善作用,为临床治疗提供依据。方法选取新安国际医院2018年1月至2020年6月收治的儿童支气管哮喘100例作为研究对象。按照随机数字表法将患者分为两组,各50例。对照组给予支气管扩张剂、糖皮质激素等常规治疗,观察组在常规治疗的基础上给予维生素D3辅助治疗。治疗9 d后,观察比较两组患者的临床疗效及不良反应,并对治疗前后肺功能第1秒用力呼气容积(FEV1)、用力肺活量(FVC)水平,气道炎症指标肿瘤坏死因子α(TNF-α)、白细胞介素10(IL-10)、白细胞介素5(IL-5)水平进行对比分析。结果观察组总有效率为94.00%(47/50),明显高于对照组的80.00%(40/50),差异均有统计学意义(χ^(2)=4.332,P<0.05)。治疗后,两组患者的FEV1、FVC水平均明显升高(均P<0.05),且观察组的FEV1、FVC水平[(1.47±0.42)L、(2.09±0.64)L]均明显高于对照组[(1.21±0.34)L、(1.85±0.47)L],差异均有统计学意义(t=2.137、3.402,均P<0.05);治疗后,两组患者的TNF-α、IL-5水平明显降低(均P<0.001),IL-10水平明显升高(均P<0.001),且观察组的TNF-α、IL-5水平[(0.58±0.13)ng/L、(39.37±3.54)ng/L]均明显低于对照组[(0.92±0.23)ng/L、(61.36±5.72)ng/L],IL-10水平[(215.62±13.25)ng/L]明显高于对照组[(127.28±9.27)ng/L],差异均有统计学意义(t=9.099、38.628、23.115,均P<0.001)。结论维生素D3辅助治疗对儿童支气管哮喘治疗效果显著,可促进患者肺功能水平及气道炎症指标的改善,值得临床推广应用。

Objective To investigate the effects of vitamin D3 adjuvant therapy on pulmonary function and airway inflammation in children with bronchial asthma,providing evidence for clinical treatment of bronchial asthma.Methods 100 children with bronchial asthma who received treatment in Xin'an International Hospital from January 2018 to June 2020 were included in this study.They were randomly assigned to receive either conventional treatments(such as bronchodilator and glucocorticoid treatments)(control group,n=50)or conventional treatment combined with vitamin D3 adjuvant treatment(observation group,n=50)for 9 days.Clinical efficacy and adverse reactions were compared between the two groups.Before and after treatment,forced expiratory volume in 1 second(FEV1),forced vital capacity(FVC),tumor necrosis factor-alpha(TNF-α),interleukin 10(IL-10),and interleukin-5(IL-5)levels were compared between the two groups.Results Total effective rate in the observation group was significantly higher than that in the control group[94.00%(47/50)vs.80.00%(40/50),χ^(2)=4.332,P<0.05].After treatment,FEV1 and FVC levels in each group were significantly increased compared with before treatment(both P<0.05).After treatment,FEV1 and FVC levels in the observation group were(1.47±0.42)L and(2.09±0.64)L,respectively,which were significantly higher than those in the control group[(1.21±0.34)L,(1.85±0.47)L,t=2.137,3.402,both P<0.05].After treatment,TNF-αand IL-5 levels in each group were significantly deceased(both P<0.001),and IL-10 level was significantly increased(P<0.001),compared with before treatment in the same group.After treatment,TNF-αand IL-5 levels in the observation group were(0.58±0.13)ng/L and(39.37±3.54)ng/L,respectively,which were significantly lower than those in the control group[(0.92±0.23)ng/L,(61.36±5.72)ng/L,t=9.099,38.628,both P<0.001].After treatment,IL-10 level in the observation group was significantly higher than that in the control group[(215.62±13.25)ng/L vs.(127.28±9.27)ng/L,t=23.115,P<0.001].Conclusion Vitamin D3 adjuvant therapy for the treatment of bronchial asthma in children can help promote pulmonary function recovery and reduce airway inflammation,which is worthy of clinical application.